Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-01-10

FDA Approved: NEURACEQ — Supplemental Application (Lantheus Biosciences Ltd.)

View source ↗

Summary

FDA approved a supplemental application for NEURACEQ (florbetaben F-18) from Lantheus Biosciences Ltd., granting continued approval for its PET imaging use in i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NEURACEQ (Florbetaben F 18)

Snippet

SUPPL AP for NEURACEQ (FLORBETABEN F 18)